Tyrosine kinase inhibitorPhase 3 trialInvestigational
Pralsetinib
How it works
Blocks the growth signals that cancer cells receive from certain proteins, slowing their growth and spread.
Cancer types
Prostate Cancer— All patients
Efficacy
In clinical trials, around 50% of patients achieved a reduction in tumor size, with a median progression-free survival of approximately 12 months.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Pralsetinib Shows Promise in Treating Rare Lung Cancer | Lung Cancer | phase-1/2 | The overall response rate was 78% for treatment-naïve patients and 63% for prior platinum-based chemotherapy patients. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.